🇺🇸 AZD9291 in United States
4 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 4
Most-reported reactions
- Hyperkalaemia — 2 reports (50%)
- Blood Creatine Phosphokinase Increased — 1 report (25%)
- Transaminases Increased — 1 report (25%)
Other Oncology approved in United States
Frequently asked questions
Is AZD9291 approved in United States?
AZD9291 does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for AZD9291 in United States?
Soroka University Medical Center is the originator. The local marketing authorisation holder may differ — check the official source linked above.